Million

Kitty

<h3 id="key-takeaways">Key Takeaways</h3>
<ul>
 <li>Shares of NextCure (NXTC) soared more than 300% Tuesday following the announcement of an all-stock combination with private biotech firm Avere Therapeutics</li>
 <li>A simultaneous $320 million private financing round was secured, with Fairmount and Hansoh Pharmaceutical serving as lead investors</li>
 <li>Following the transaction’s completion in the latter half of 2026, the merged entity will list on Nasdaq under the new ticker symbol AVRX</li>
 <li>Current NextCure shareholders will retain roughly 1.21% ownership in the post-merger company</li>
 <li>The strategic combination focuses on AVR-001, an innovative oral once-weekly IL-23 receptor antagonist being developed for psoriasis and ulcerative colitis treatment</li>
</ul>
Shares of NextCure (NXTC) rocketed more than 300% higher Tuesday as the clinical-stage biotechnology firm unveiled plans to merge with Avere Therapeutics, a private company, in a transaction supported by $320 million in new capital.
<a href="https://knockoutstocks.com/stock/NXTC" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/NXTC/embed" alt="NXTC Stock Card"> NextCure, Inc., NXTC </a>
While the dramatic intraday surge captured attention, NXTC shares still trade approximately 84% below their year-to-date starting point, with the company carrying a modest $7.87 million market capitalization prior to the announcement.
Under the terms of the all-stock agreement, the post-merger entity will adopt the Avere Therapeutics name and begin trading on the Nasdaq exchange using the ticker AVRX. Transaction completion is anticipated during the second half of 2026.
The accompanying $320 million private placement features $251 million in convertible notes that will be exchanged for common shares upon deal closure. Leading the financing round are Fairmount and Hansoh Pharmaceutical, joined by Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, and Wellington Management.
At the heart of this strategic combination sits Avere’s primary development candidate, AVR-001 — an orally administered, once-weekly IL-23 receptor antagonist targeting inflammatory diseases such as psoriasis and ulcerative colitis.
Avere secured licensing rights to AVR-001 from Hansoh for all territories excluding Greater China. The licensing arrangement provided Hansoh with $120 million upfront, with potential additional payments reaching $2.18 billion tied to development achievements and commercial sales, alongside tiered royalty payments.
Proceeds from the new capital raise will support a Phase 2b clinical trial in psoriasis patients, initiate a Phase 3 psoriasis study, and launch a Phase 2b ulcerative colitis investigation. An Investigational New Drug application for AVR-001 has already been cleared by US regulators, with Phase 2b enrollment targeted for early 2027 and topline data expected during the first half of 2028.
<h3 id="leadership-structure-post-merger">Leadership Structure Post-Merger</h3>
Dr. Andrew Cheng, currently serving as Avere’s CEO, will assume leadership of the combined organization as Chief Executive Officer, President, and Chairman of the Board. Kitty Yale will transition into the Chief Development Officer role, with William White taking the CFO position and Brett Pletcher serving as General Counsel.
Michael Richman, NextCure’s current Chief Executive, characterized the transaction as “a compelling opportunity” enabling current shareholders to gain exposure to AVR-001’s clinical advancement.
<h3 id="implications-for-nextcure-shareholders">Implications for NextCure Shareholders</h3>
Existing NextCure shareholders will control approximately 1.21% of the post-combination company — a reflection of the significant disparity in valuation between the two organizations.
Additionally, they will receive contingent value rights providing access to 90% of any net proceeds generated from potential monetization of NextCure’s current pipeline programs during a two-year period following deal completion.
Trading activity Tuesday exceeded 44 million shares. By comparison, NXTC’s three-month average daily volume stands at approximately 37,000 shares.
Analyst consensus rates NXTC as a Moderate Buy, supported by two Buy recommendations issued within the past three months, with a mean price target of $20 per share.
The post <a href="https://blockonomi.com/nextcure-nxtc-stock-skyrockets-300-following-320-million-avere-therapeutics-merger-agreement/" rel="noopener noreferrer nofollow">NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement

Table of Contents

Blockonomi

Other articles published on Jul 14, 2026

Join our free newsletter for daily crypto updates!